Gulcihan Cinar Kaya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gulcihan Cinar Kaya has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Ayca Tas
Sivas Cumhuriyet Üniversitesi
3 shared publications - Mert Atas
Sivas Cumhuriyet Üniversitesi
2 shared publications - Sevil Ceyhan Doğan
Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Sivas Cumhuriyet University, Sivas 58140, Turkey
2 shared publications - Zuhal Tuncbilek
Sivas Cumhuriyet Üniversitesi
2 shared publications - Ahmet Karadağ
Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Sivas Cumhuriyet University, 58140 Sivas, Türkiye
1 shared publication - Cemile Zontul
Sivas Cumhuriyet Üniversitesi
1 shared publication
Latest Publications
- Open Access
- 9 July 2026
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (7) , 696
Peripheral Blood Gene Expression and Protein Profiles of Purinergic and Glutamatergic Signaling Components and PD-L1 in Gastric Cancer: A Cross-Sectional Study
Gastric cancer remains a major cause of cancer-related mortality worldwide, highlighting the need for an improved understanding of its molecular mechanisms. Purinergic and glutamatergic signaling pathways, immune checkpoint molecules, and oxidative stress are thought to contribute to tumor biology; however, their combined evaluation in gastric cancer is limited. Methods: Gene expression levels of glutamate receptor ionotropic N-Methyl-D-aspartate 2A (GRIN2A), purinergic receptor P2X1 (P2RX1), and programmed death-ligand 1 (PD-L1/CD274) were analyzed using real-time PCR, while serum protein levels were determined by ELISA. Total antioxidant status (TAS) and total oxidant status (TOS) were also measured to assess systemic oxidative balance. Results: Gene expression analysis revealed an increased expression trend for P2RX1 in the gastric cancer group compared with healthy controls, whereas GRIN2A and CD274 (PD-L1) expression levels showed numerical decreases. Serum concentrations of GRIN2A and PD-L1, as well as TAS and TOS levels, were numerically higher in patients with gastric cancer; however, none of these differences reached statistical significance (p > 0.05). Likewise, serum P2RX1 levels did not differ significantly between groups. Receiver operating characteristic (ROC) analysis demonstrated area under the curve (AUC) values close to 0.5 for all evaluated parameters, indicating limited discriminatory and diagnostic performance. Conclusions: These findings suggest that these molecular markers may reflect disease-related biological alterations rather than serve as independent circulating diagnostic biomarkers in gastric cancer.
- 9 July 2026
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (7) , 696
Open AccessPeripheral Blood Gene Expression and Protein Profiles of Purinergic and Glutamatergic Signaling Components and PD-L1 in Gastric Cancer: A Cross-Sectional Study
Gastric cancer remains a major cause of cancer-related mortality worldwide, highlighting the need for an improved understanding of its molecular mechanisms. Purinergic and glutamatergic signaling pathways, immune checkpoint molecules, and oxidative stress are thought to contribute to tumor biology; however, their combined evaluation in gastric cancer is limited. Methods: Gene expression levels of glutamate receptor ionotropic N-Methyl-D-aspartate 2A (GRIN2A), purinergic receptor P2X1 (P2RX1), and programmed death-ligand 1 (PD-L1/CD274) were analyzed using real-time PCR, while serum protein levels were determined by ELISA. Total antioxidant status (TAS) and total oxidant status (TOS) were also measured to assess systemic oxidative balance. Results: Gene expression analysis revealed an increased expression trend for P2RX1 in the gastric cancer group compared with healthy controls, whereas GRIN2A and CD274 (PD-L1) expression levels showed numerical decreases. Serum concentrations of GRIN2A and PD-L1, as well as TAS and TOS levels, were numerically higher in patients with gastric cancer; however, none of these differences reached statistical significance (p > 0.05). Likewise, serum P2RX1 levels did not differ significantly between groups. Receiver operating characteristic (ROC) analysis demonstrated area under the curve (AUC) values close to 0.5 for all evaluated parameters, indicating limited discriminatory and diagnostic performance. Conclusions: These findings suggest that these molecular markers may reflect disease-related biological alterations rather than serve as independent circulating diagnostic biomarkers in gastric cancer.
- Open Access
Receptor–Ligand Biomarker Profile in Ankylosing Spondylitis: Associations Between AXL/MERTK Expression, Circulating GAS6 and Protein S Levels, and Disease Activity
(1) Background: Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease associated with immune dysregulation. The TYRO3, AXL, and MER (TAM) signaling pathway, comprising AXL receptor tyrosine kinase (AXL), MER tyrosine kinase (MERTK), growth arrest-specific 6 (GAS6), and Protein S, is a key regulator of immune homeostasis. This study investigated these receptor–ligand components in patients with AS. (2) Methods: A total of 45 patients with AS and 44 healthy controls were enrolled. Serum GAS6 and Protein S levels were measured by ELISA, and AXL and MERTK expression levels were analyzed by RT-qPCR. Clinical and inflammatory parameters were also evaluated. (3) Results: ESR, CRP, and IL-6 levels were significantly higher, whereas Protein S levels were significantly lower in patients with AS than in controls. No significant differences were observed in GAS6, AXL, or MERTK expression levels, although lower expression trends were detected in patients. Logistic regression analysis identified CRP, IL-6, Protein S, and AXL expression as variables independently associated with AS. ROC analysis demonstrated significant discriminatory performance for AXL expression. (4) Conclusions: Alterations in the TAM signaling pathway, particularly reduced Protein S levels and altered AXL expression, may contribute to immune dysregulation and persistent inflammation in AS.
Open AccessReceptor–Ligand Biomarker Profile in Ankylosing Spondylitis: Associations Between AXL/MERTK Expression, Circulating GAS6 and Protein S Levels, and Disease Activity
(1) Background: Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease associated with immune dysregulation. The TYRO3, AXL, and MER (TAM) signaling pathway, comprising AXL receptor tyrosine kinase (AXL), MER tyrosine kinase (MERTK), growth arrest-specific 6 (GAS6), and Protein S, is a key regulator of immune homeostasis. This study investigated these receptor–ligand components in patients with AS. (2) Methods: A total of 45 patients with AS and 44 healthy controls were enrolled. Serum GAS6 and Protein S levels were measured by ELISA, and AXL and MERTK expression levels were analyzed by RT-qPCR. Clinical and inflammatory parameters were also evaluated. (3) Results: ESR, CRP, and IL-6 levels were significantly higher, whereas Protein S levels were significantly lower in patients with AS than in controls. No significant differences were observed in GAS6, AXL, or MERTK expression levels, although lower expression trends were detected in patients. Logistic regression analysis identified CRP, IL-6, Protein S, and AXL expression as variables independently associated with AS. ROC analysis demonstrated significant discriminatory performance for AXL expression. (4) Conclusions: Alterations in the TAM signaling pathway, particularly reduced Protein S levels and altered AXL expression, may contribute to immune dysregulation and persistent inflammation in AS.
- Open Access
- 31 March 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (7) , 3164
Serum Levels of Glutamatergic (GRIN1) and Purinergic (P2RX1/P2RY2) Receptors in Patients with Fibromyalgia
Fibromyalgia (FM) is a chronic pain syndrome characterized by central sensitization, in which glutamatergic and purinergic signaling pathways are thought to play critical roles. This study aimed to evaluate the diagnostic potential of serum glutamate ionotropic receptor N-methyl-D-aspartate type subunit 1 (GRIN1), purinergic receptor P2X 1 (P2RX1), and purinergic receptor P2Y 2 (P2RY2) levels in patients with FM. A total of 93 newly diagnosed FM patients and 93 age- and sex-matched healthy controls were included in the study. Serum levels of GRIN1, P2RX1, and P2RY2 were measured using enzyme-linked immunosorbent assay (ELISA). Receiver operating characteristic (ROC) curve analysis was performed to assess the diagnostic performance of these biomarkers. ROC analysis demonstrated good diagnostic accuracy for all three biomarkers. The area under the curve (AUC) values were 0.817 for GRIN1, 0.778 for P2RX1, and 0.842 for P2RY2 (p < 0.001 for all). At optimal cut-off values, GRIN1, P2RX1, and P2RY2 showed sensitivities of 91.4%, 78.5%, and 92.5%, and specificities of 72.00%, 75.3%, and 80.6%, respectively. Serum GRIN1, P2RX1, and P2RY2 levels exhibit strong diagnostic performance in FM and may serve as promising biomarkers reflecting altered glutamatergic and purinergic signaling in disease pathophysiology.
- 31 March 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (7) , 3164
Open AccessSerum Levels of Glutamatergic (GRIN1) and Purinergic (P2RX1/P2RY2) Receptors in Patients with Fibromyalgia
Fibromyalgia (FM) is a chronic pain syndrome characterized by central sensitization, in which glutamatergic and purinergic signaling pathways are thought to play critical roles. This study aimed to evaluate the diagnostic potential of serum glutamate ionotropic receptor N-methyl-D-aspartate type subunit 1 (GRIN1), purinergic receptor P2X 1 (P2RX1), and purinergic receptor P2Y 2 (P2RY2) levels in patients with FM. A total of 93 newly diagnosed FM patients and 93 age- and sex-matched healthy controls were included in the study. Serum levels of GRIN1, P2RX1, and P2RY2 were measured using enzyme-linked immunosorbent assay (ELISA). Receiver operating characteristic (ROC) curve analysis was performed to assess the diagnostic performance of these biomarkers. ROC analysis demonstrated good diagnostic accuracy for all three biomarkers. The area under the curve (AUC) values were 0.817 for GRIN1, 0.778 for P2RX1, and 0.842 for P2RY2 (p < 0.001 for all). At optimal cut-off values, GRIN1, P2RX1, and P2RY2 showed sensitivities of 91.4%, 78.5%, and 92.5%, and specificities of 72.00%, 75.3%, and 80.6%, respectively. Serum GRIN1, P2RX1, and P2RY2 levels exhibit strong diagnostic performance in FM and may serve as promising biomarkers reflecting altered glutamatergic and purinergic signaling in disease pathophysiology.